Depomed (DEPO) Shares are Up 6.24%

Depomed (DEPO) has been under a strong bear grip, hence the stock is down -1% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 5.71% in the past 1 week. The stock has risen by 6.24% in the past week indicating that the buyers are active at lower levels, but the stock is down -1.13% in the past 4 weeks.

The stock has recorded a 20-day Moving Average of 0.78% and the 50-Day Moving Average is 5.55%.The 200 Day SMA reached 17.34%. Depomed, Inc. is up 1.65% in the last 3-month period. Year-to-Date the stock performance stands at 15.44%.


Depomed (NASDAQ:DEPO): After opening at $20.63, the stock dipped to an intraday low of $20.37 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $20.96 and the buying power remained strong till the end. The stock closed at $20.93 for the day, a gain of 1.60% for the day session. The total traded volume was 819,150. The stocks close on the previous trading day was $20.6.

Depomed, Inc. is a specialty pharmaceutical company focused on pain and other central nervous system (CNS) conditions. The Companys products include Gralise (gabapentin), CAMBIA (diclofenac potassium for oral solution), Zipsor (diclofenac potassium) and Lazanda (fentanyl). Gralise is a once-daily product for the management of postherpetic neuralgia (PHN). CAMBIA is a non-steroidal anti-inflammatory drug (NSAID) for the acute treatment of migraine attacks. Zipsor, a liquid filled capsule, is a NSAID for the treatment of mild to moderate acute pain. Lazanda nasal spray is used for the management of break through pain in cancer patients 18 years of age and older who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. It also has a portfolio of license agreements based on its Acuform gastroretentive drug delivery technology. The Companys product DM-1992 has completed a Phase II trial for Parkinsons disease.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.